The estimated Net Worth of Invest Corp Pillar Partners... is at least $3.75 Milion dollars as of 20 January 2021. Invest Partners owns over 1,699,765 units of Idera Pharmaceuticals stock worth over $691,512 and over the last 5 years Invest sold IDRA stock worth over $3,059,577.
Invest has made over 2 trades of the Idera Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Invest sold 1,699,765 units of IDRA stock worth $3,059,577 on 20 January 2021.
The largest trade Invest's ever made was selling 1,699,765 units of Idera Pharmaceuticals stock on 20 January 2021 worth over $3,059,577. On average, Invest trades about 442,427 units every 10 days since 2020. As of 20 January 2021 Invest still owns at least 1,608,167 units of Idera Pharmaceuticals stock.
You can see the complete history of Invest Partners stock trades at the bottom of the page.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... oraz Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: